Solriamfetol (Monograph)

Brand name: Sunosi
Drug class: Wakefulness-promoting Agents
- Dopamine- and Norepinephrine-reuptake Inhibitors
Chemical name: [(2R)-2-amino-3-phenylpropyl] carbamate, monohydrochloride
Molecular formula: C₁₀H₁₄N₂O₂•HCl
CAS number: 178429-65-7

Medically reviewed by Drugs.com on Nov 6, 2024. Written by ASHP.

Introduction

Dopamine- and norepinephrine-reuptake inhibitor (DNRI); a wakefulness-promoting agent.

Uses for Solriamfetol

Obstructive Sleep Apnea

Symptomatic treatment of obstructive sleep apnea to improve wakefulness in patients with excessive daytime sleepiness. Use as an adjunct to standard treatment(s) for the underlying obstruction (e.g., nasal continuous positive airway pressure [CPAP]). Not indicated to treat the underlying airway obstruction, and not a substitute for standard treatments for airway obstruction. Provide standard treatments for ≥1 month prior to initiating solriamfetol and continue such treatments during solriamfetol therapy.

Narcolepsy

Symptomatic treatment of narcolepsy to improve wakefulness in patients with excessive daytime sleepiness (designated an orphan drug by FDA for treatment of narcolepsy).

Solriamfetol Dosage and Administration

General

Ensure BP is adequately controlled before initiating solriamfetol. (See Cardiovascular Effects under Cautions.)

Administration

Oral Administration

Administer orally once daily upon awakening. Avoid administration within 9 hours of planned bedtime because of the potential for sleep interference.

Administer without regard to food.

Dosage

Available as solriamfetol hydrochloride; dosage expressed in terms of solriamfetol.

Adults

Obstructive Sleep Apnea

Oral

Initially, 37.5 mg once daily. Based on efficacy and tolerability, may double dosage at intervals of at least 3 days up to a maximum of 150 mg once daily. Recommended dosage range is 37.5–150 mg once daily. (See Prescribing Limits under Dosage and Administration.)

Narcolepsy

Oral

Initially, 75 mg once daily. Based on efficacy and tolerability, may double dosage at intervals of at least 3 days up to a maximum of 150 mg once daily. Recommended dosage range is 75–150 mg once daily. (See Prescribing Limits under Dosage and Administration.)

Prescribing Limits

Adults

Obstructive Sleep Apnea

Oral

Maximum 150 mg once daily. Dosages >150 mg daily do not provide sufficient additional clinical benefit to outweigh dose-related adverse effects. (See Cardiovascular Effects and also see Common Adverse Effects under Cautions.)

Narcolepsy

Oral

Special Populations

Hepatic Impairment

Manufacturer makes no specific dosage recommendations for patients with hepatic impairment. (See Hepatic Impairment under Cautions.)

Renal Impairment

Mild renal impairment (eGFR 60–89 mL/minute per 1.73 m²): Dosage adjustment not required.

Moderate renal impairment (eGFR 30–59 mL/minute per 1.73 m²): Initially, 37.5 mg once daily; based on efficacy and tolerability, may increase dosage after at least 7 days to a maximum of 75 mg once daily.

Severe renal impairment (eGFR 15–29 mL/minute per 1.73 m²): 37.5 mg once daily; maximum recommended dosage is 37.5 mg daily.

End-stage renal disease (eGFR <15 mL/minute per 1.73 m²): Use not recommended. (See Pharmacokinetics and also see Renal Impairment under Cautions.)

Geriatric Patients

Dosage adjustments based on eGFR may be required. Consider lower dosages and close monitoring. (See Geriatric Use under Cautions.)

Cautions for Solriamfetol

Contraindications

Current or recent (within 14 days) therapy with a monoamine oxidase (MAO) inhibitor. (See Cardiovascular Effects under Cautions and also see Specific Drugs under Interactions.)

Warnings/Precautions

Cardiovascular Effects

Produces dose-dependent increases in systolic and diastolic BP and heart rate.

Chronically elevated BP increases the risk of major adverse cardiovascular events (e.g., stroke, MI, cardiovascular death). The magnitude of the increase in absolute risk is dependent on the increase in BP and underlying cardiovascular risk. Many patients with obstructive sleep apnea or narcolepsy have multiple cardiovascular risk factors (e.g., hypertension, diabetes mellitus, hyperlipidemia, high body mass index [BMI]).

Assess BP and control hypertension prior to initiating solriamfetol. Regularly monitor BP during therapy and appropriately manage new or exacerbated hypertension.

Caution advised in patients at higher risk of major adverse cardiovascular events, particularly older patients and those with known cardiovascular and cerebrovascular disease or preexisting hypertension. Caution also advised in patients receiving concomitant therapy with drugs known to increase BP and heart rate.

Patients with moderate or severe renal impairment may be at increased risk for elevations in BP and heart rate because the drug's half-life is prolonged in such patients.

Periodically reassess the need for continued solriamfetol therapy. If increases in BP or heart rate occur and cannot be managed by solriamfetol dosage reduction or other appropriate medical intervention, consider drug discontinuance.

Psychiatric Effects

Adverse psychiatric effects (e.g., anxiety, insomnia, irritability) reported.

Not evaluated in patients with psychosis or bipolar disorders; caution advised in patients with a history of such disorders.

Patients with moderate or severe renal impairment may be at higher risk for psychiatric symptoms because the drug's half-life is prolonged in such patients.

Monitor patients for the possible emergence or exacerbation of psychiatric symptoms. If psychiatric symptoms develop, consider dosage reduction or drug discontinuance.

Abuse, Misuse, and Dependence Potential

Classified as Schedule IV (C-IV) drug. Abuse potential of solriamfetol (200, 600, and 1200 mg) similar to or lower than that of the Schedule IV drug phentermine hydrochloride (45 and 90 mg) in individuals with a history of recreational stimulant use.

Efficacy and safety studies in patients with obstructive sleep apnea or narcolepsy provided no evidence that abrupt discontinuance produced a consistent pattern of adverse events suggestive of physical dependence or withdrawal in individual patients.

Carefully evaluate patients for a history of recent drug abuse, particularly alcohol or stimulant (e.g., amphetamine, cocaine, methylphenidate) abuse; closely monitor patients with such history for possible signs of misuse or abuse (e.g., incrementation of doses, drug-seeking behavior).

Specific Populations

Pregnancy

Available data from case reports are not sufficient to determine solriamfetol-associated risks of major birth defects, spontaneous abortion, or adverse maternal or fetal outcomes. Teratogenicity, fetal toxicity, and developmental toxicity observed in animal studies.

Pregnancy registry available ([Web] or 877-283-6220).

Lactation

Not known whether solriamfetol or its metabolites are distributed into human milk; solriamfetol distributes into milk in rats. Also not known whether the drug affects breast-fed infants or affects milk production.

Consider the developmental and health benefits of breast-feeding along with the mother’s clinical need for solriamfetol and any potential adverse effects on the breast-fed child from the drug or from the underlying maternal condition. Monitor nursing infants for adverse effects (e.g., agitation, insomnia, anorexia, reduced weight gain) potentially resulting from exposure to the drug through breast milk.

Pediatric Use

Safety and efficacy in pediatric patients not established.

Geriatric Use

No clinically important differences in safety or efficacy observed between geriatric patients and younger adults.

Age does not appear to substantially affect pharmacokinetics of solriamfetol; no dosage adjustments made in clinical trials that included patients ≥65 of age. However, dosage adjustment may be necessary because geriatric patients are more likely to have decreased renal function and solriamfetol is eliminated mainly by the kidneys; consider use of lower dosages and close monitoring.

Hepatic Impairment

Hepatic impairment is not expected to affect the pharmacokinetics of solriamfetol; the drug undergoes minimal metabolism.

Renal Impairment

Solriamfetol clearance decreases with worsening renal function. (See Pharmacokinetics.) Adjust dosage in patients with moderate to severe renal impairment. (See Renal Impairment under Dosage and Administration.) Use not recommended in those with end-stage renal disease.

Patients with moderate or severe renal impairment may be at increased risk for elevations in BP and heart rate because the drug's half-life is prolonged in such patients.

Common Adverse Effects

Headache, nausea, decreased appetite, insomnia, anxiety. In clinical trials, headache, nausea, decreased appetite, anxiety, diarrhea, and dry mouth were dose related.

Drug Interactions

Undergoes minimal metabolism in vitro. Does not inhibit CYP isoenzymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4 in vitro; does not induce CYP isoenzyme 1A2, 2B6, or 3A4, or uridine-diphosphate glucuronosyltransferase (UGT) 1A1 at clinically relevant concentrations.

Low-avidity substrate of organic cation transporter (OCT) 2, multidrug and toxin extrusion transporter (MATE) 1, and organic cation transporters novel (OCTN) 1 and 2. Weakly inhibits OCT2 and MATE1; does not inhibit OCT1, MATE2-K, OCTN1, or OCTN2. Does not appear to be a substrate or inhibitor of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transport polypeptide (OATP) 1B1 or 1B3, or organic anion transporter (OAT) 1 or 3.

Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

Clinically important interactions involving major CYP isoenzymes not expected.

Drugs Affecting or Affected by Transport Systems

Clinically important interactions involving major transport systems not expected.

Drugs that Increase BP or Heart Rate

Concomitant use of solriamfetol with other drugs that increase BP and/or heart rate not evaluated; use such combination therapy with caution. (See Cardiovascular Effects under Cautions.)

Specific Drugs

Drug	Interaction	Comments
Dopaminergic drugs	Possible pharmacodynamic interaction with drugs that increase dopamine concentrations or bind to dopaminergic receptors	Interactions with dopaminergic drugs not evaluated to date; use concomitantly with caution
MAO inhibitors	Possible increased risk of hypertensive reactions, potentially resulting in death, stroke, MI, aortic dissection, ophthalmologic complications, eclampsia, pulmonary edema, and renal failure	Solriamfetol is contraindicated in patients who are currently receiving or have recently (within 14 days) received an MAO inhibitor

Solriamfetol Pharmacokinetics

Absorption

Bioavailability

Exhibits linear pharmacokinetics over a dose range of 42–1008 mg; once-daily administration is expected to result in minimal accumulation.

Readily (95%) absorbed following oral administration. Under fasted conditions, peak plasma concentration is achieved at a median of 2 hours (range: 1.25–3 hours).

Food

Administration with a high-fat meal delays peak plasma concentration by approximately 1 hour, but results in minimal change in peak concentration or AUC.

Special Populations

Mild, moderate, or severe renal impairment (eGFR 60–89, 30–59, or <30 mL/minute per 1.73 m², respectively): AUC increased by 53, 129, or 339%, respectively, compared with individuals with normal renal function. Renal impairment does not appreciably alter peak plasma concentration or time to peak plasma concentration.

End-stage renal disease (eGFR <15 mL/minute per 1.73 m²): AUC increased by approximately fourfold (with hemodialysis) or fivefold (without hemodialysis) compared with individuals with normal renal function.

Distribution

Extent

Not known whether distributed into human milk.

Plasma Protein Binding

Approximately 13–19%.

Elimination

Metabolism

Undergoes minimal metabolism.

Elimination Route

Eliminated mainly (95%) in urine as unchanged drug; ≤1% of administered dose recovered as the minor inactive metabolite N-acetylsolriamfetol. Active tubular secretion is likely involved in renal clearance of the parent drug.

Half-life

Exhibits first-order elimination with mean apparent elimination half-life of about 7.1 hours.

Special Populations

Age, sex, and race do not have clinically important effects on the pharmacokinetics of solriamfetol.

Mild, moderate, or severe renal impairment (eGFR 60–89, 30–59, or <30 mL/minute per 1.73 m², respectively): Half-life is increased by approximately 1.2-, 1.9-, or 3.9-fold, respectively.

End-stage renal disease (eGFR <15 mL/minute per 1.73 m²): Half-life is >100 hours. A 4-hour hemodialysis session removes approximately 21% of a solriamfetol dose.

Stability

Storage

Oral

Tablets

20–25°C (may be exposed to 15–30°C).

Actions

Binds to dopamine and norepinephrine transporters with low affinity; inhibits reuptake of dopamine and norepinephrine with low potency.
Has no appreciable binding affinity for serotonin transporter; does not inhibit serotonin reuptake. Also has no appreciable binding affinity for dopamine, serotonin, norepinephrine, GABA, adenosine, histamine, orexin, benzodiazepine, muscarinic acetylcholine, or nicotinic acetylcholine receptors.
Exact mechanism by which solriamfetol promotes wakefulness in patients with excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy is not known but may involve inhibition of dopamine and norepinephrine reuptake resulting from binding of the drug to dopamine and norepinephrine transporters in the brainstem arousal systems.

Advice to Patients

Advise patients to read the manufacturer's patient information (medication guide).
Advise patients that solriamfetol is a controlled substance and has the potential to be abused. Advise patients to keep their medication in a secure place and to dispose of unused solriamfetol as recommended in the medication guide.
Inform patients with obstructive sleep apnea that solriamfetol is not indicated to treat the underlying airway obstruction and that they should use standard treatments (e.g., CPAP) as prescribed. Solriamfetol is not a substitute for such therapy.
Advise patients that solriamfetol can increase BP and pulse rate and that they should be monitored for such effects.
Instruct patients to contact their clinician if they experience anxiety, insomnia, irritability, agitation, or symptoms of psychosis or bipolar disorders.
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. Advise women who are breast-feeding to monitor their infants for adverse effects such as agitation, insomnia, anorexia, and reduced weight gain. Encourage pregnant women who have been exposed to solriamfetol to enroll in the manufacturer's pregnancy registry. (See Pregnancy under Cautions.)
Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Subject to control under the Federal Controlled Substances Act of 1970 as a schedule IV (C-IV) drug.